Advertisement

Advertisement

HK:3681 Stock Latest News

SinoMab Sets 2026 AGM to Renew Board, Auditor and Share Capital Mandates

Company AnnouncementsSinoMab Sets 2026 AGM to Renew Board, Auditor and Share Capital Mandates

SinoMab Starts Phase 2 Trial of IL‑25 Antibody SM17 in Chinese Atopic Dermatitis Patients

PremiumCompany Announcements

SinoMab Starts Phase 2 Trial of IL‑25 Antibody SM17 in Chinese Atopic Dermatitis Patients

28d ago

SinoMab Updates Board and Committee Structure to Clarify Governance Roles

PremiumCompany Announcements

SinoMab Updates Board and Committee Structure to Clarify Governance Roles

29d ago

SinoMab BioScience Announces Resignations of Two Non-Executive Directors

PremiumCompany Announcements

SinoMab BioScience Announces Resignations of Two Non-Executive Directors

29d ago

SinoMab Bioscience Sets Out Board and Committee Structure

PremiumCompany Announcements

SinoMab Bioscience Sets Out Board and Committee Structure

29d ago

SinoMab Reports Positive Phase 1 Data for Subcutaneous SM17 in China

PremiumCompany AnnouncementsSinoMab Reports Positive Phase 1 Data for Subcutaneous SM17 in China

1M ago

SinoMab Grants 11.6 Million Share Options to Key Employees

Company Announcements

SinoMab Grants 11.6 Million Share Options to Key Employees

1M ago

SinoMab Narrows Loss as Key Antibody Programs Advance and Funding Base Expands

Company Announcements

SinoMab Narrows Loss as Key Antibody Programs Advance and Funding Base Expands

1M ago

SinoMab Ends Haikou Lease as It Shifts to Asset-Light Manufacturing Model

PremiumCompany Announcements

SinoMab Ends Haikou Lease as It Shifts to Asset-Light Manufacturing Model

2M ago

SinoMab BioScience Sets March Board Meeting to Approve 2025 Annual Results

PremiumCompany Announcements

SinoMab BioScience Sets March Board Meeting to Approve 2025 Annual Results

2M ago

SinoMab’s New SM17 Trial Puts Atopic Dermatitis Back in Focus for HK:3681 Investors

PremiumCompany Announcements

SinoMab’s New SM17 Trial Puts Atopic Dermatitis Back in Focus for HK:3681 Investors

2M ago

SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease

PremiumCompany Announcements

SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease

2M ago

SinoMab’s SM17 IND Application for IBD Accepted by NMPA

PremiumCompany AnnouncementsSinoMab’s SM17 IND Application for IBD Accepted by NMPA

5M ago

SinoMab Doses First Cohort with Subcutaneous SM17 in China Study

Company Announcements

SinoMab Doses First Cohort with Subcutaneous SM17 in China Study

7M ago

SinoMab BioScience Announces New Company Secretary Appointment

Company Announcements

SinoMab BioScience Announces New Company Secretary Appointment

7M ago

SinoMab BioScience Reports Key Progress in Clinical Trials for 2025

PremiumCompany Announcements

SinoMab BioScience Reports Key Progress in Clinical Trials for 2025

8M ago

SinoMab Completes New Share Subscription to Raise HK$50.68 Million

PremiumCompany Announcements

SinoMab Completes New Share Subscription to Raise HK$50.68 Million

8M ago

SinoMab BioScience Schedules Board Meeting to Review Interim Results

PremiumCompany Announcements

SinoMab BioScience Schedules Board Meeting to Review Interim Results

8M ago

SinoMab Completes New Share Subscription to Boost Drug Development

PremiumCompany Announcements

SinoMab Completes New Share Subscription to Boost Drug Development

9M ago

SinoMab BioScience Enters Strategic Biomedicine Partnership

PremiumCompany AnnouncementsSinoMab BioScience Enters Strategic Biomedicine Partnership

9M ago

SinoMab BioScience Grants Over 46 Million Share Options to Employees and Service Providers

Company Announcements

SinoMab BioScience Grants Over 46 Million Share Options to Employees and Service Providers

9M ago

SinoMab Bioscience Announces New Share Subscription Agreement

Company Announcements

SinoMab Bioscience Announces New Share Subscription Agreement

9M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >